Merck, SML2875-5MG, DCC-2618

Biochem/physiol Actions
DCC-2618 is an orally active, potent type II switch pocket (SP) inhibitor against c-KIT (IC₅₀ = 4 nM/WT, 8 nM/V654A, 18 nM/T670I, 5 nM/D816H, 14 nM/D816V) and PDGFR. DCC-2618 locks c-KIT & PDGFR in an inactive conformation and is effective against multiple clinical forms of mutations resistant to type I ATP (catalytic)-site inhibitors Imatinib and Sunitinib. DCC-2618 inhibits cellular c-KIT activation (IC₅₀ = 36 nM/WT, 2 nM/ex 11 del, 7 nM/ex 11 del & V654A, 53 nM/V560D & D820A) and is efficacious against KIT mutants-mediated cancer growth in cultres (IC₅₀ = 2 nM; GIST with KIT D816Y) and in mice in vivo (50 mg/kg b.i.d. p.o.; GIST with KIT delW557K558/Y823D, AML with KIT N822K).
Orally active, potent type II switch pocket (SP) c-KIT & PDGFR inhibitor against multiple clinical forms of mutations resistant to Imatinib and Sunitinib.